Dan Estes, Ph.D. joined the board of Arcutis in 2017. He is also a Partner on the Frazier Life Sciences team, where he has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 8 years, focusing on investments in both development-stage and commercial-stage pharmaceutical companies. Dr. Estes serves on the boards of Semnur Pharmaceuticals, Outpost Medicine, Sierra Oncology (NASDAQ: SRRA), and Cirius Therapeutics. He has also been involved with Frazier’s investments in Acerta Pharma (acquired by AZ), Tobira (acquired by Allergan), PreCision Dermatology (acquired by Valeant), Millendo (NASDAQ: MLND), and Entasis (NASDAQ: ETTX). Prior to joining Frazier, Dr. Estes was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells. Dan also holds a B.S. in Electrical Engineering from Stanford University.